GB2612458B - Enzymes with RuvC domains - Google Patents
Enzymes with RuvC domains Download PDFInfo
- Publication number
- GB2612458B GB2612458B GB2217378.5A GB202217378A GB2612458B GB 2612458 B GB2612458 B GB 2612458B GB 202217378 A GB202217378 A GB 202217378A GB 2612458 B GB2612458 B GB 2612458B
- Authority
- GB
- United Kingdom
- Prior art keywords
- enzymes
- ruvc domains
- ruvc
- domains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022320P | 2020-05-08 | 2020-05-08 | |
| US202063032464P | 2020-05-29 | 2020-05-29 | |
| US202063116155P | 2020-11-19 | 2020-11-19 | |
| US202163180570P | 2021-04-27 | 2021-04-27 | |
| PCT/US2021/031136 WO2021226363A1 (en) | 2020-05-08 | 2021-05-06 | Enzymes with ruvc domains |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB202217378D0 GB202217378D0 (en) | 2023-01-04 |
| GB2612458A GB2612458A (en) | 2023-05-03 |
| GB2612458B true GB2612458B (en) | 2025-04-09 |
Family
ID=78468763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2217378.5A Active GB2612458B (en) | 2020-05-08 | 2021-05-06 | Enzymes with RuvC domains |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209332A1 (https=) |
| EP (2) | EP4467642A3 (https=) |
| JP (2) | JP7778087B2 (https=) |
| KR (1) | KR20230021657A (https=) |
| CN (1) | CN116096892A (https=) |
| AU (1) | AU2021267379A1 (https=) |
| CA (1) | CA3177828A1 (https=) |
| GB (1) | GB2612458B (https=) |
| MX (1) | MX2022014067A (https=) |
| WO (1) | WO2021226363A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178933A2 (en) | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| US10913941B2 (en) * | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| WO2021202568A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| CA3205865A1 (en) * | 2021-01-22 | 2022-07-28 | Brian C. Thomas | Novel engineered and chimeric nucleases |
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| CA3243006A1 (en) * | 2021-12-21 | 2025-02-27 | Alia Therapeutics Srl | TYPE II CAS PROTEINS AND THEIR APPLICATIONS |
| WO2023137451A1 (en) * | 2022-01-14 | 2023-07-20 | Arbor Biotechnologies, Inc. | Compositions comprising an rna guide targeting cd38 and uses thereof |
| WO2023194359A1 (en) * | 2022-04-04 | 2023-10-12 | Alia Therapeutics Srl | Compositions and methods for treatment of usher syndrome type 2a |
| CA3267752A1 (en) * | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| US20180371498A1 (en) * | 2017-06-23 | 2018-12-27 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US20190062735A1 (en) * | 2016-03-04 | 2019-02-28 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| WO2019097305A2 (en) * | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3617311A1 (en) * | 2017-03-30 | 2020-03-04 | Kyoto University | Method for inducing exon skipping by genome editing |
| EP4308699A1 (en) * | 2021-03-19 | 2024-01-24 | Metagenomi, Inc. | Multiplex editing with cas enzymes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015161276A2 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| US20190136230A1 (en) * | 2016-05-06 | 2019-05-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| EP3500967A1 (en) * | 2016-08-17 | 2019-06-26 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| EP3724326A1 (en) * | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019165168A1 (en) * | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| AU2019252925A1 (en) * | 2018-04-13 | 2020-07-30 | Sigma-Aldrich Co. Llc. | Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins |
| CN113227374A (zh) * | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| CA3241703C (en) * | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
-
2021
- 2021-05-06 WO PCT/US2021/031136 patent/WO2021226363A1/en not_active Ceased
- 2021-05-06 CN CN202180049158.6A patent/CN116096892A/zh active Pending
- 2021-05-06 AU AU2021267379A patent/AU2021267379A1/en active Pending
- 2021-05-06 JP JP2022567462A patent/JP7778087B2/ja active Active
- 2021-05-06 MX MX2022014067A patent/MX2022014067A/es unknown
- 2021-05-06 EP EP24192681.5A patent/EP4467642A3/en not_active Withdrawn
- 2021-05-06 GB GB2217378.5A patent/GB2612458B/en active Active
- 2021-05-06 EP EP21800930.6A patent/EP4146800A1/en not_active Withdrawn
- 2021-05-06 CA CA3177828A patent/CA3177828A1/en active Pending
- 2021-05-06 KR KR1020227042270A patent/KR20230021657A/ko active Pending
-
2022
- 2022-11-07 US US18/053,232 patent/US20240209332A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027249A patent/JP2025090617A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190062735A1 (en) * | 2016-03-04 | 2019-02-28 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP3617311A1 (en) * | 2017-03-30 | 2020-03-04 | Kyoto University | Method for inducing exon skipping by genome editing |
| WO2019097305A2 (en) * | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US20180371498A1 (en) * | 2017-06-23 | 2018-12-27 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| EP4308699A1 (en) * | 2021-03-19 | 2024-01-24 | Metagenomi, Inc. | Multiplex editing with cas enzymes |
Non-Patent Citations (4)
| Title |
|---|
| Moon S.B.et al., "Recent advances in the CRISPR genome editing tool set", Experimental & Molecular Medicine, Epub.05 November 2019, Vol. 51, article number 130, pp. 1-11. Abstract; pages 2-4, 8; table 1; figures 1-3 * |
| Nature Biomedical Engineering, vol. 3, no. 12, 2019, Kortleve Dian et al., Orthotopic editing of T-cell receptors, pages 949-950. * |
| NCBI GenBank Accession NO. WP_061212298.1, "HNH endonuclease [ Dermabacter hominis]" , 27 February 2016. The whole document. * |
| Tang, Y et al., "Class 2 CRISPR/Cas;an expanding biotechnology toolbox for and beyond genome editing", Cell & Bioscience, 2018, vol 8, article number 59, pages 1-13. Abstract; pages 2-5; figures 1-3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230021657A (ko) | 2023-02-14 |
| GB202217378D0 (en) | 2023-01-04 |
| CA3177828A1 (en) | 2021-11-11 |
| JP7778087B2 (ja) | 2025-12-01 |
| CN116096892A (zh) | 2023-05-09 |
| AU2021267379A1 (en) | 2022-12-08 |
| EP4467642A2 (en) | 2024-11-27 |
| EP4146800A1 (en) | 2023-03-15 |
| JP2023533417A (ja) | 2023-08-03 |
| EP4467642A3 (en) | 2025-04-16 |
| WO2021226363A1 (en) | 2021-11-11 |
| MX2022014067A (es) | 2023-02-22 |
| JP2025090617A (ja) | 2025-06-17 |
| US20240209332A1 (en) | 2024-06-27 |
| GB2612458A (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2612458B (en) | Enzymes with RuvC domains | |
| CA3241703A1 (en) | Enzymes with ruvc domains | |
| EP4165177A4 (en) | ENZYMES WITH RUVC DOMAINS | |
| EP3882345A4 (en) | CRISPR-CAS12J ENZYME AND SYSTEM | |
| EP3870697A4 (en) | GMO ENZYMES | |
| EP4093863A4 (en) | CRISPR-CAS ENZYMES WITH ENHANCED ON-TARGET ACTIVITY | |
| IL281171A (en) | Cellulose-synthase-like enzymes and their uses | |
| IL289202A (en) | Uridine diphosphate-dependent glycosyltransferase enzyme | |
| EP3924477A4 (en) | ENZYMES WITH RUVC DOMAINS | |
| EP4330386A4 (en) | Enzymes with ruvc domains | |
| EP3843774A4 (en) | REPROGRAMMING HEART CELLS WITH MYOCARDINE AND ASCL1 | |
| EP4392561A4 (en) | Enzymes with RuVC domains | |
| EP3821021A4 (en) | BACTERIAL CONJUGATIVE SYSTEM AND THERAPEUTIC USES THEREOF | |
| EP3496539A4 (en) | MAGNETICALLY IMMOBILIZED BIOCID ENZYMS AND BIOCID CHEMICALS | |
| EP4077649A4 (en) | MICROBIAL PRODUCTION OF MOGROL AND MOGROSIDES | |
| GB201917688D0 (en) | SHC enzymes and enzyme variants | |
| EP3775255A4 (en) | METABOLIC TEST FOR BACTERIAL GROWTH AND GRAMTYPING | |
| GB2617659B (en) | Enzymes with RuvC domains | |
| GB202017421D0 (en) | Enzyme method | |
| HK40111693A (en) | Enzymes with ruvc domains | |
| HK40100816A (en) | Enzymes with ruvc domains | |
| HK40089109A (en) | Enzymes with ruvc domains | |
| HK40065111A (en) | Enzymes with ruvc domains | |
| HK40110360A (en) | Enzymes with hepn domains | |
| CA3284206A1 (en) | Enzymes with ruvc domains |